Barclays (BCS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

Barclays BCS reported fourth-quarter 2024 net income attributable to ordinary equity holders of £956 million ($1.22 billion) against a net loss of £111 million in the prior-year quarter.

Barclays (BCS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to ...

Isobel van Daesdonk and Scott Willard join Barclays as Managing Directors within the Americas Financial Sponsors Group “We are delighted to welcome Isobel and Scott to Barclays,” said ...

Barclays (BCS) is headquartered in London, and is in the Finance sector. The stock has seen a price change of 19.19% since the start of the year. The financial holding company is currently ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the ...

Fintel reports that on March 10, 2025, Barclays downgraded their outlook for Emerson Electric (WBAG:EMR) from Equal-Weight to Underweight. There are 2,942 funds or institutions reporting positions ...

Fintel reports that on March 5, 2025, Barclays upgraded their outlook for Mosaic (NYSE:MOS) from Underweight to Equal-Weight. As of March 4, 2025, the average one-year price target for Mosaic is $ ...

“We designed Barclays Live with our clients at the forefront, recognising that they each have unique needs when it comes to research and insights,” said Brad Rogoff, Global Head of Research at ...

Barclays will remain the exclusive issuer of ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...

Fintel reports that on February 26, 2025, Barclays upgraded their outlook for Lennox International (NYSE:LII) from Equal-Weight to Overweight. As of February 19, 2025, the average one-year price ...